A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

KRAS inhibitors, cancer vaccines, and cell therapies are promising advancements in pancreatic cancer treatment, potentially improving patient outcomes. Innovative drug delivery techniques aim to ...

Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune | Cancer ...

Add Yahoo as a preferred source to see more of our stories on Google. ABC News' Becky Worley got an inside look at the Baylor College of Medicine in Houston, Texas, where researchers are making ...

DOC1021 is a first-in-class, patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic ...

Pancreatic cancer survival has finally doubled in a decade to 13 percent, a fragile but real sign that years of slow, methodical progress are beginning to add up. November is Pancreatic Cancer ...

Targeted MAPK pathway inhibition with atebimetinib contrasts with nonselective cytotoxic chemotherapy and is paired with a dose-schedule modification intended to ...

A team of researchers at the Georgetown University Lombardi Comprehensive Cancer Center published new research exploring causes and potential treatment methods for pancreatic cancer, Lombardi ...

Pancreatic cancer is the 12th most common cancer worldwide. In 2022, there were 510,992 new cases of pancreatic cancer, with China, the US, and Japan reporting the highest number of cases globally.

A new cohort study suggests that Medicaid expansion is associated with a lower mortality risk among patients with pancreatic ...